Deafness, aminoglycoside-induced
MONDO:0010799Also known as: aminoglycoside-induced hearing loss, mitochondrial isolated neurosensory hearing loss with susceptibility to aminoglycoside exposure, mitochondrial isolated sensorineural hearing loss with susceptibility to aminoglycoside exposure, mitochondrial non-syndromic neurosensory hearing loss with susceptibility to aminoglycoside exposure, mitochondrial non-syndromic sensorineural hearing loss with susceptibility to aminoglycoside exposure, deafness, aminoglycoside-induced, deafness, mitochondrial, modifier of, mitochondrial, deafness, streptomycin-induced
17 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
New drug shows promise for rare energy disorder
Disease control CompletedThis study tested a new drug called OMT-28 in 28 people with primary mitochondrial disease, a condition that affects how cells produce energy. Participants took the drug once daily for 6 months, and researchers measured safety, blood markers of inflammation, and symptoms like fat…
Phase: PHASE2 • Sponsor: Omeicos Therapeutics GmbH • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
Long-Term safety of mitochondrial drug confirmed in 101 patients
Disease control CompletedThis study looked at the safety of vatiquinone in 101 people with inherited mitochondrial disease who had already taken the drug in a previous study or treatment plan. The goal was to track any side effects until the drug became commercially available or the program ended. Partic…
Phase: PHASE3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC